SCYNEXIS, Inc. Lease, Cost
SCYNEXIS, Inc. (SCYX) reported Lease, Cost of $730.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-04
- SCYNEXIS, Inc. lease, cost for the quarter ending 2024-12-31 was $196.00K, a 4.85% decline year-over-year.
- SCYNEXIS, Inc. lease, cost for the quarter ending 2024-09-30 was $194.00K, a 7.62% decline year-over-year.
- SCYNEXIS, Inc. lease, cost for the quarter ending 2024-06-30 was $193.00K, a 8.96% decline year-over-year.
- SCYNEXIS, Inc. lease, cost for the quarter ending 2024-03-31 was $143.00K, a 36.16% decline year-over-year.
- SCYNEXIS, Inc. lease, cost for fiscal 2025 was $730.00K, a 0.55% increase from fiscal 2024.
- SCYNEXIS, Inc. lease, cost for fiscal 2024 was $726.00K, a 14.79% decline from fiscal 2023.
- SCYNEXIS, Inc. lease, cost for fiscal 2023 was $852.00K, a 19.50% increase from fiscal 2022.
- SCYNEXIS, Inc. lease, cost for fiscal 2022 was $713.00K, a 1.57% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $730.00K 10-K · filed 2026-03-04 | |||
| 2024-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $390.00K derived: sum of 2 quarters · filed 2026-03-04 | $583.00K derived: sum of 3 quarters · filed 2026-03-04 | $726.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $194.00K 10-Q · filed 2024-11-06 | $387.00K derived: sum of 2 quarters · filed 2024-11-06 | $530.00K 10-Q · filed 2024-11-06 | $736.00K derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-06-30 | $193.00K 10-Q · filed 2024-08-08 | $336.00K 10-Q · filed 2024-08-08 | $542.00K derived: sum of 3 quarters · filed 2025-03-12 | $752.00K derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-03-31 | $143.00K 10-Q · filed 2024-05-08 | $349.00K derived: sum of 2 quarters · filed 2025-03-12 | $559.00K derived: sum of 3 quarters · filed 2025-03-12 | $771.00K derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $416.00K derived: sum of 2 quarters · filed 2025-03-12 | $628.00K derived: sum of 3 quarters · filed 2025-03-12 | $852.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $210.00K 10-Q · filed 2024-11-06 | $422.00K derived: sum of 2 quarters · filed 2024-11-06 | $646.00K 10-Q · filed 2024-11-06 | $848.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $212.00K 10-Q · filed 2024-08-08 | $436.00K 10-Q · filed 2024-08-08 | $638.00K derived: sum of 3 quarters · filed 2024-08-08 | $812.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $224.00K 10-Q · filed 2024-05-08 | $426.00K derived: sum of 2 quarters · filed 2024-05-08 | $600.00K derived: sum of 3 quarters · filed 2024-05-08 | $774.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $376.00K derived: sum of 2 quarters · filed 2024-03-28 | $550.00K derived: sum of 3 quarters · filed 2024-03-28 | $713.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $174.00K 10-Q · filed 2023-11-13 | $348.00K derived: sum of 2 quarters · filed 2023-11-13 | $511.00K 10-Q · filed 2023-11-13 | $697.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $174.00K 10-Q · filed 2023-08-14 | $337.00K 10-Q · filed 2023-08-14 | $523.00K derived: sum of 3 quarters · filed 2023-08-14 | $698.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $163.00K 10-Q · filed 2023-05-10 | $349.00K derived: sum of 2 quarters · filed 2023-05-10 | $524.00K derived: sum of 3 quarters · filed 2023-05-10 | $700.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $361.00K derived: sum of 2 quarters · filed 2023-03-31 | $537.00K derived: sum of 3 quarters · filed 2023-03-31 | $702.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $175.00K 10-Q · filed 2022-11-09 | $351.00K derived: sum of 2 quarters · filed 2022-11-09 | $516.00K 10-Q · filed 2022-11-09 | $696.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $176.00K 10-Q · filed 2022-08-15 | $341.00K 10-Q · filed 2022-08-15 | $521.00K derived: sum of 3 quarters · filed 2022-08-15 | $696.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $164.00K 10-Q · filed 2022-05-12 | $345.00K derived: sum of 2 quarters · filed 2022-05-12 | $520.00K derived: sum of 3 quarters · filed 2022-05-12 | $692.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $356.00K derived: sum of 2 quarters · filed 2022-03-29 | $528.00K derived: sum of 3 quarters · filed 2022-03-29 | $715.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $175.00K 10-Q · filed 2021-11-10 | $347.00K derived: sum of 2 quarters · filed 2021-11-10 | $534.00K 10-Q · filed 2021-11-10 | $716.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $172.00K 10-Q · filed 2021-08-16 | $359.00K 10-Q · filed 2021-08-16 | $541.00K derived: sum of 3 quarters · filed 2021-08-16 | $715.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $187.00K 10-Q · filed 2021-05-17 | $369.00K derived: sum of 2 quarters · filed 2021-05-17 | $543.00K derived: sum of 3 quarters · filed 2021-05-17 | $717.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $356.00K derived: sum of 2 quarters · filed 2021-03-29 | $530.00K derived: sum of 3 quarters · filed 2021-03-29 | $705.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $174.00K 10-Q · filed 2019-11-12 | $348.00K derived: sum of 2 quarters · filed 2019-11-12 | $523.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $174.00K 10-Q · filed 2019-08-07 | $349.00K 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $175.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |